<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481231</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00531-52</org_study_id>
    <nct_id>NCT03481231</nct_id>
  </id_info>
  <brief_title>In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma</brief_title>
  <acronym>IMMUNOGLIO</acronym>
  <official_title>In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) is the most frequent brain tumor. Currently survival is poor and few&#xD;
      treatments are available. Recent data show that there is no immune privilege of the central&#xD;
      nervous system (CNS) and that GBM are invaded by effector CD8 T cells, letting us hypothesis&#xD;
      that GBM growth is dependent of immunosurveillance.&#xD;
&#xD;
      The aim of this study is to better understand the antitumor immune response against GBM to&#xD;
      unravel new effectors and immunosuppressive pathways important for the regulation of&#xD;
      anticancer immunity and to discover new immune activating strategies with the objectives to&#xD;
      isolate subgroups of GBMs that could benefit from an immunotherapy approach. To achieve this&#xD;
      goal, GBM tumor samples and a blood sample will be collected during the initial tumor&#xD;
      resection.&#xD;
&#xD;
      The sites involved in the recruitment of the patients will be the neurosurgical teams in&#xD;
      Brussel, Dijon, Nantes and Padova.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :&#xD;
&#xD;
      The primary objective is to determine for each of the 3 molecular subtypes of glioblastoma&#xD;
      the predictive performance on 1-year overall survival of in situ immune parameters&#xD;
&#xD;
      Secondary objectives :&#xD;
&#xD;
      To identify the best combination of in vivo immune parameters that is predictive of 1-year&#xD;
      overall survival To determine the impact of immune parameters on overall survival Create a&#xD;
      collection of biological samples&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">September 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Years</target_duration>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Determination for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters</description>
  </primary_outcome>
  <enrollment type="Anticipated">311</enrollment>
  <condition>Glioblastoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      24 ml blood sample + tumor samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a glioblastoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly diagnosed, brain tumor&#xD;
&#xD;
          2. Gross or near total resection of the contrast-enhancing tumor mass decides by the&#xD;
             neurosurgeron.&#xD;
&#xD;
          3. Subjects ≥18 and ≤75 years of age at surgery&#xD;
&#xD;
          4. Patients must be able to understand and sign the informed consent documents indicating&#xD;
             that they are aware of the investigational nature of this study.&#xD;
&#xD;
          5. Confirmation of the diagnosis of grade IV GBM by the local pathologist with an&#xD;
             independent neuropathologist who will review this diagnosis&#xD;
&#xD;
          6. Primary therapy must consist of surgical resection with the intent for a gross or near&#xD;
             total resection of the contrast-enhancing tumor mass, followed by conventional&#xD;
             external beam radiation therapy and concurrent temozolomide chemotherapy.&#xD;
&#xD;
          7. Tumor biopsy for biological analysis has to be performed before using ultrasonic&#xD;
             surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with other type of primary brain tumor or metastases&#xD;
&#xD;
          2. Patients with only biopsy performed for the diagnosis&#xD;
&#xD;
          3. Subjects under guardianship, curatorship or judicial protection&#xD;
&#xD;
          4. Female subjects who are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François GHIRINGHELLI, PU-PU</last_name>
    <phone>03.80.73.34.02</phone>
    <email>FGhiringhelli@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>03.45.34.81.16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Ghiringhelli, PU-PH</last_name>
      <phone>03 80 73 75 06</phone>
      <email>fghiringhelli@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Rederstorff</last_name>
      <email>erederstorff@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Vincent</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Walid FARAH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Céline SALAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Florence</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Camilla BONAUDO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Università di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro DELLA PUPPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco VOLPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanna MANDRUZZATO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>tumors and blood samples</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

